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The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of
chemotherapy plus 12 months of trastuzumab, with or without endocrine therapy. Several trials have
investigated modifications of the standard treatment that are shorter and less resource-demanding
(de-escalation) or regimens that aim at dual HER2 inhibition or include longer than 12 months of
HER2-targeted treatment (escalation). Seven randomized trials investigate shorter than 12 months of
trastuzumab treatment duration. The shorter durations were not statistically inferior to the 1-year dura-
tion in the 3 trials with survival results available, but 2 of the trials were small and 1 had a relatively short
follow-up time of the patients at the time of reporting. The pathological complete response (pCR) rates
were numerically higher in all 9 randomized trials that compared chemotherapy plus dual HER2 inhibi-
tion consisting of trastuzumab plus either lapatinib, neratinib, or pertuzumab with chemotherapy plus
trastuzumab as neoadjuvant treatments, but the superiority of chemotherapy plus dual HER2-
inhibition over chemotherapy plus trastuzumab remains to be demonstrated in the adjuvant setting.
One year of adjuvant trastuzumab was as effective as 2 years of trastuzumab in the HERA trial, and
was associated with fewer side-effects. Extending 1-year adjuvant trastuzumab treatment with 1 year
of neratinib improved disease-free survival in the ExteNET trial, but the patient follow-up times are still
short, and no overall survival benefit was reported. Several important trials are expected to report results
in the near future and may modify the current standard.
 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Human epidermal growth factor receptor 2 (HER2) is a tyrosine
kinase encoded by the ERBB2 gene, located at 17q12. ERBB2 ampli-
fication leads to overexpression of the HER2 protein [1,2]. HER2-
positive breast cancers frequently give rise to distant metastases
at visceral sites as compared to luminal A cancers [3,4]. In the
era that preceded the modern systemic therapies even small
node-negative HER2-positive cancers 62 cm in diameter were
associated with a 20–30% risk for distant metastases [5,6]. HER2-
positive breast cancers are usually identified with either presence
of HER2 protein overexpression in breast tumor tissue at immuno-
histochemistry or ERBB2 amplification at in situ hybridization. The
HER2-status of the primary breast tumor and paired distant metas-
tases are discordant in about 10% of the patients [7,8]. ERBB2 is
amplified in 15–25% of breast carcinomas, the frequency being
influenced by the criteria used to define HER2-positivity [9].Patients with early HER2-positive breast cancer benefit from
HER2-targeted systemic therapy. The only exception is patients
with small (65 mm) node-negative cancer, when local therapy
alone is considered sufficient [10,11]. Patients with HER2-
positive cancer that expresses estrogen receptors (ER) and/or pro-
gesterone receptors (PgR) are treated with adjuvant endocrine
therapy as other patients with steroid hormone receptor-positive
breast cancer [10].
This review discusses the current systemic adjuvant and neoad-
juvant HER2-targeted treatments for early HER2-positive breast
cancer, and the attempts to modify the treatment by either making
it shorter, less toxic, and less resource-demanding (de-escalation),
or more effective with dual HER2 inhibition or extending the treat-
ment duration (escalation). These 2 strategies are not necessarily
mutually exclusive, as dual HER2-inhibition may potentially be
integrated in regimens of short duration.
Current standard treatment
The currently recommended standard adjuvant treatment for
patients with early HER2-positive breast cancer is chemotherapy
2 H. Joensuu / Cancer Treatment Reviews 52 (2017) 1–11plus trastuzumab administered for 1 year. Chemotherapy consists
usually of a few cycles of an anthracycline-containing regimen fol-
lowed by a taxane, the latter given concurrently with trastuzumab.
Docetaxel, carboplatin, and trastuzumab (TCH) is an option, partic-
ularly for patients who are unsuitable for anthracycline-containing
treatment [10,12]. Even patients with small HER2-positive cancer
benefit from adjuvant trastuzumab [13], but anthracyclines may
not be needed when treating node-negative cancer 61 cm in diam-
eter, as such patients have a high disease-free survival (DFS) rate
when treated with 1 year of trastuzumab plus paclitaxel [14] or 4
cycles of docetaxel and cyclophosphamide [15].
Adjuvant trastuzumab was first investigated in 4 large random-
ized trials as the treatment of early HER2-positive breast cancer,
the National Surgical Adjuvant Breast and Bowel Project (NSABP)
trial B-31, the North Central Cancer Treatment Group (NCCTG) trial
N9831, HERA, and the Breast Cancer International Research Group
(BCIRG) trial 006 [16,17,12]. The same trastuzumab dose
(2 mg/week) and the same duration (12 months) were selected
for evaluation in all 4 trials. The 12-month duration was studied
also in 2 smaller randomized adjuvant trials, the NOAH [18] and
the PACS 04 [19] trials. The choice of the 12-month duration for
study was arbitrary [20], and no clinical or preclinical evidence
to support this duration existed. The Food and Drug Administration
(FDA) approved adjuvant trastuzumab in 2006, as there was
compelling evidence for efficacy and the safety profile was
favorable. In the absence of data from other durations than the
12-month duration, the 1-year duration became the standard.
In a Cochrane Breast Cancer Group literature search that
included 8 randomized controlled adjuvant trials and 11,991
patients, the combined hazard ratios (HRs) for DFS and overall sur-
vival (OS) favored very significantly the trastuzumab-containing
regimens over the same chemotherapy without trastuzumab.
There were 40% fewer cancer recurrences in the groups treated
with trastuzumab (HR 0.60, 95% confidence interval [CI] 0.51–
0.71) and 34% fewer deaths (HR 0.66, 95% CI 0.57–0.77) [21]. The
favorable effect of adjuvant trastuzumab on survival appears dur-
able. In the planned joint analysis of the B-31 and the N9831 trials
based on a median follow-up time of 8.4 years of the patients, add-
ing trastuzumab to chemotherapy improved the 10-year OS rate
from 75% to 84% (a relative improvement of 37% as compared with
the chemotherapy only group) and the 10-year DFS rate from 62%
to 74% (a relative improvement of 40%) [22].
Trastuzumab is generally well tolerated, but periodical moni-
toring of the cardiac left ventricular ejection fraction (LVEF) is con-
sidered mandatory as trastuzumab increases the risk of congestive
heart failure (CHF). In a meta-analysis the absolute overall risk for
high-grade CHF among 18,111 patients who participated in 6 ran-
domized controlled adjuvant trials evaluating trastuzumab was
1.4%, and the relative risk as compared with the control groups
3.2 [23]. Patients treated with adjuvant trastuzumab for 2 years
had a higher risk for cardiac adverse effects than those treated
for 1 year [24], whereas a 9-week course of trastuzumab was asso-
ciated with no detectable risk [23]. Another overview analysis
found an increased risk for severe heart failure in patients treated
with trastuzumab-based versus non-trastuzumab-based regimens
of 2.5% and 0.4%, respectively (a relative risk of 5.11) [21]. Almost
all cardiac failures are detected within the first 2 years since start-
ing adjuvant trastuzumab. In one study, follow-up for a median of
9.2 years revealed only 2 additional diagnoses of CHF among 1046
patients after the first 3 years of follow-up, indicating that late
onset of trastuzumab-related cardiac failure is rare [25]. The LVEF
recovers in most patients who develop heart failure after trastuzu-
mab discontinuation and initiation of therapy for heart failure
[24–26]. A low LVEF, hypertension medication, coronary artery
disease, and age have been identified as risk factors for
trastuzumab-related cardiac failure [25–27]. Yet, as geriatricpatients were underrepresented in the major adjuvant trials [28]
and those with cardiac risk factors were excluded, the risk may
be higher in population-based studies [29]. In a cohort study
among breast cancer patients aged >65 and with full Medicare
coverage, the rate of CHF was 29.4% among trastuzumab users as
compared to 18.9% among the non-users [27].Trastuzumab chemotherapy partners
Administration of some chemotherapy agents concomitantly
with trastuzumab likely improves efficacy substantially. Preclinical
studies suggest that docetaxel, vinorelbine, cyclophosphamide,
and platinum salts are synergistic with trastuzumab [30,31]. The
combination of docetaxel plus trastuzumab has been compared
to single-agent trastuzumab in 2 randomized trials in advanced
HER2-positive breast cancer [32,33]. In these 2 trials, the patients
allocated to docetaxel plus trastuzumab had a median time to dis-
ease progression of 14.6 and 9.4 months compared to only 3.7 and
3.4 months, respectively, in the groups allocated to single-agent
trastuzumab, suggesting that adding concomitant docetaxel to
trastuzumab approximately triples the time to progression com-
pared to trastuzumab alone. Furthermore, the only randomized
trial (N9831) that compared concomitant administration of adju-
vant trastuzumab with chemotherapy (weekly paclitaxel) to
sequential administration found the 5-year DFS rate to favor con-
comitant administration (84.4% vs. 80.1%, respectively) [34]. These
data suggest that the chemotherapy partners given concomitantly
with trastuzumab are important for the overall regimen efficacy.
With the exception of the B-31 and the N9831 trials that shared
2 treatment arms [16], the companion chemotherapy agents varied
in the randomized trials that evaluated adjuvant trastuzumab, and
in the HERA and the PACS 04 trials all trastuzumab was adminis-
tered only after chemotherapy completion [17,19].Randomized de-escalation trials
Seven randomized trials ask the question whether comparable
efficacy to 1-year adjuvant trastuzumab can be achieved with a
shorter regimen, but with fewer side-effects (Table 1). In 4 of these
trials all trastuzumab is administered concomitantly with
chemotherapy in the experimental arm in an attempt to exploit
drug synergism (FinHer, E2198, SOLD, and Short-HER trials), and
3 trials compare 6-month to 12-month duration of trastuzumab
(the Hellenic trial, PHARE, and PERSEPHONE) [35–42].
FinHer was the first randomized trial to evaluate a shorter than
the 12-month duration of adjuvant trastuzumab, and may be con-
sidered as the first de-escalation trial. FinHer accrued 1010
patients with early breast cancer from 17 centers in Finland in
October 2000 to September 2003. The patients were assigned to
either 3 3-weekly cycles of docetaxel or weekly vinorelbine, each
followed by 3 3-weekly cycles of FEC. The 232 patients with
HER2-positive disease had a second randomization to weekly tras-
tuzumab, given upfront and concomitantly with either docetaxel
or vinorelbine, or to observation [35]. The selection of docetaxel
and vinorelbine as the companion agents with trastuzumab was
based on preclinical data that suggested drug synergism [30].
The duration of 9 weeks of HER2-targeted therapy resulted from
the duration of 3 3-weekly given chemotherapy cycles. The Finnish
Breast Cancer Group sponsored the trial, and funding for trastuzu-
mab was obtained from the government budget of Finland. Some-
what unexpectedly, the patients treated with 9-week trastuzumab
plus docetaxel or vinorelbine had a comparable hazard ratio for
cancer recurrence (0.42, 95% CI 0.21–0.83) as was achieved in the
B-31, N9831, and HERA trials with 1-year duration of trastuzumab
[35], suggesting that the brief administration of trastuzumab with
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H. Joensuu / Cancer Treatment Reviews 52 (2017) 1–11 3synergistic chemotherapy agents warrants further research. In Fin-
Her, 1 patient in the trastuzumab group and 2 patients in the
observation group had symptomatic heart failure [36].
The E2198 trial accrued 227 patients with axillary-node posi-
tive, stage II or IIIA HER2-positive breast cancer in the USA in
1999 to 2000. The patients were randomly assigned to weekly
paclitaxel for 12 weeks plus weekly trastuzumab given for
10 weeks concomitantly with paclitaxel, followed by 4 3-weekly
cycles of doxorubicin plus cyclophosphamide (AC) or to the same
therapy plus 1 year of trastuzumab administered after completion
of chemotherapy (Table 1). The primary objective was to evaluate
safety, particularly CHF. DFS and OS were secondary objectives.
Very few patients had CHF (4 in the 1-year trastuzumab group
and 3 in the 10-week group). DFS or OS did not differ significantly
between the groups after a median of 6.4 years of follow-up [37].
The Synergism Or Long Duration (SOLD) trial (NCT00593697) is
the follow-up trial of FinHer with a design that resembles that of
E2198, except that 3 3-weekly cycles of docetaxel are administered
in place of weekly paclitaxel, FEC (fluorouracil, epirubicin,
cyclophosphamide) in place of AC, and the duration of trastuzumab
given concomitantly with a taxane is 9 weeks instead of 10 weeks
(Table 1). The only difference between the 2 allocation groups in
SOLD is post-chemotherapy trastuzumab, which is not adminis-
tered in the experimental arm. The target population consists of
patients with either node-negative or node-positive breast cancer;
node-negative patients with breast cancer diameter 61 cm are
excluded. The primary objective is DFS. SOLD is a non-inferiority
trial. Accrual was completed in December 2014 with 2136 patients
entered from 7 countries. The first results, based on a minimum
median follow-up of approximately 5 years, are expected in 2017.
The Short-HER trial (NCT00629278) compares the most effec-
tive N9831 trial arm (ACx4, followed by taxane plus concomitant
trastuzumab for 12 months) with the docetaxel arm of the FinHer
trial (Table 1). Some variability in the chemotherapy regimens in
the 12-month trastuzumab arm is allowed (either doxorubicin or
epirubicin, and either paclitaxel or docetaxel may be adminis-
tered). Besides trastuzumab administration duration, also the
number of scheduled chemotherapy cycles and the sequence of
taxanes and anthracyclines differ between the arms [38]. The trial
has completed accrual with approximately 1200 patients entered.
The first results are anticipated in 2017.
Three randomized trials compare 6–12 months of adjuvant
trastuzumab. Two of these trials, the Hellenic trial [39] and PHARE
[40], have reported results, but the median follow-up times of the
patients were still relatively short at the time of reporting.
The Hellenic Oncology Research Group trial assigned 481
patients with node-positive or high-risk node-negative HER2-
positive breast cancer to 4 cycles of 2-weekly FEC (epirubicin dose
75 mg/m2), followed by 4 cycles of 2-weekly docetaxel (75 mg/m2)
with leukocyte growth factor support between 2004 and 2012 [39].
Trastuzumab was started concomitantly with docetaxel, and then
continued based on random allocation either for 12 or 6 months.
The patients were followed up for a median of approximately
4 years. The 3-year DFS rates were high in both groups (Table 1).
The hazard ratio tended to favor the standard duration group,
but there was no significant difference between the groups in
DFS. The HR for OS was not reported, but there was no statistical
difference in OS between the groups, and numbers of patients
who died were small (8 in the 6-month group; 10 in the 12-
month group). Only 2 patients had cardiac toxicity.
A total of 3384 patients with stage I to III HER2-positive breast
cancer were entered from 156 French sites in 2006 to 2010 to
PHARE. The patients were required to have received at least 4
cycles of chemotherapy. Randomization took place after comple-
tion of chemotherapy, and the patients were assigned either to
continue trastuzumab up to 12 months or to stop at 6 months of
4 H. Joensuu / Cancer Treatment Reviews 52 (2017) 1–11treatment. The chemotherapy regimens were variable, but most
patients were treated with an anthracycline and a taxane-
containing regimen. Most patients received trastuzumab concomi-
tantly with chemotherapy (12-month group, 57%; 6-month group,
56%). No re-staging was done at the time of randomization. After a
median follow-up time of 3.5 years, 175 and 219 patients had can-
cer recurrence or had died, leading to a hazard ratio of 1.28 (95% CI
1.05–1.56) in favor of the 12-month group. This difference was not
significant, as the trial was designed as a non-inferiority trial with
a non-inferiority margin of 1.15, leading to a P value of 0.29. The
numbers of deaths also favored numerically the longer duration.
In subgroup analyses DFS was similar among patients with ER-
positive cancer and among those treated with concomitant
chemotherapy and trastuzumab, whereas patients with ER-
negative cancer who were treated with sequential chemotherapy
and trastuzumab benefitted from the 12-month duration of trastu-
zumab [40]. The incidence of CHF was 0.7% and 0.5% in the 12 and
6-month groups, respectively, and the incidence of cardiac dys-
function 5.9% and 3.4% (P = 0.001) [41]. Overall, PHARE thus failed
to show inferiority of the 6-month administration of trastuzumab.
The PERSEPHONE trial (NCT00712140) is a sister trial of PHARE
that aims to accrue 4000 patients with early breast cancer from
multiple centers located in the U.K. [42]. The patients receive stan-
dard chemotherapy regimens as per institutional practice either as
adjuvant chemotherapy or neoadjuvant chemotherapy, and either
concurrently with or sequentially to trastuzumab, and trastuzu-
mab for either 6 or 12 months based on random allocation. Ran-
domization occurs before the patient receives the 10th cycle of
trastuzumab. PERSEPHONE is a non-inferiority trial to detect 3%
non-inferiority in terms of DFS and OS. No results are yet available,
but are expected in 2017.
In sum, while standard duration of adjuvant trastuzumab
remains as 12 months, non-inferiority of the shorter regimens
could not be demonstrated in E2198, the Hellenic trial, or in
PHARE. Yet, the results of the Hellenic trial, and particularly those
of PHARE, tend to favor the 12-month treatment. The median
follow-up time of the study patients is still relatively short in these
trials. In the HERA trial that compared 1-year to 2-year adjuvant
trastuzumab treatment, the early survival results at about 3 years
from the date of randomization appeared to favor the 2-year group,
but this difference between the groups disappeared with longer
follow-up [43], suggesting that in some patients trastuzumab pro-
hibits the growth of occult metastases, but may not eradicate
them. In PHARE, the difference in favor of the 12-month group
was detected in the subgroup with ER-negative disease treated
with sequential chemotherapy and trastuzumab, which timing of
trastuzumab administration is no longer preferred [10].
Besides the timing and duration of trastuzumab administration,
the partner drugs to trastuzumab varied between the trials. Hypo-
thetically, the duration of trastuzumab administration might
become relatively less important as the efficacy of the drug combi-
nations increase. The timing of randomization also varied. While in
the FinHer, E2198, SOLD, and the Hellenic trial randomization was
carried out prior to starting systemic therapy, randomization was
done after completion of chemotherapy in PHARE, and prior to
the 10th trastuzumab cycle in PERSEPHONE. The timing of ran-
domization may influence the study patient populations, as the
patients who progress rapidly or who do not tolerate the therapy
become excluded when randomization is done after chemother-
apy. Staging might be more rigorous when the key staging exami-
nations are mandated by a study protocol, these possibly
preventing patients with overt undetectable metastases from
entering the study. As patients with overtly metastatic disease
benefit from maintained HER2-targeted therapy [44,45], less
rigorous staging might favor the longer durations of adjuvant
HER2-targeted treatments.Randomized escalation trials with extended duration of HER2-
targeted therapy
Two large randomized trials have investigated longer than
12 months of adjuvant HER2-targeted therapy as the treatment
of early breast cancer, the HERA [43] and the ExteNET [46] trials
(Table 2).
HERA is the only trial that has evaluated longer than the 12-
month duration of adjuvant trastuzumab. In 2001 to 2005, 1552
patients with early HER2-positive breast cancer were allocated to
1 year of trastuzumab and 1553 patients to 2 years of trastuzumab
after completion of chemotherapy. The patients had been followed
up for a median of 8 years at the time of the first reporting of the
results. At this mature stage, 367 patients in each group had cancer
recurrence or had died resulting in a HR of 0.99 (95% CI, 0.85–1.14).
The numbers of patients who died were also similar in the 2
groups, 186 in the 12-month group and 196 in the 24-month
group. More patients in the 24-month group had grade 3–4
adverse events (20.4% vs. 16.3%) and decreases in the LVEF (7.2%
vs. 4.1%) as compared to the 1-year group [43]. These results sug-
gest that 2 years of adjuvant trastuzumab cannot be recommended
for the standard therapy, as 12 months of trastuzumab is equally
effective, but better tolerated and less costly.
Neratinib is an orally administered, irreversible inhibitor of
HER1, HER2, and HER4. In the ExteNET trial, 2840 women were
assigned in 2009 to 2011 at the time when they had completed
12 months of adjuvant trastuzumab to either neratinib or placebo,
each to be continued for another 12 months [46]. The 2-year DFS
was 93.9% in the neratinib group and 91.0% in the placebo group
with a HR of 0.67 (95% CI, 0.50–0.91, P = 0091; Table 2). The
3-year DFS rates, reported recently, were 92.0% and 89.9%, respec-
tively (HR 0.74, 95% CI 0.56–0.96; P = 0.023) [47]. In subgroup anal-
yses neratinib was more effective in the subset of ER-positive
cancer, whereas no difference in efficacy was found among
patients with ER-negative disease. These results are interesting,
as neratinib might eradicate some cancers that are resistant to
trastuzumab, and might be more effective for some tumors that
depend also on ER-signaling. However, the median follow-up time
of the patients is still short, and no OS data were reported. Nera-
tinib appears to have little cardiac toxicity [46]. The most trouble-
some side-effect is diarrhea, but this occurs usually only in the
beginning of neratinib treatment and can be managed effectively
with prophylactic loperamide.Escalation with dual HER2 inhibition
Dual inhibition of HER2 has emerged as a method to improve
the pathological complete response (pCR) rates achieved with
neoadjuvant therapy, although the use of pCR to compare treat-
ments for survival endpoints is controversial [48–51]. Dual inhibi-
tion of HER2 has been attempted either with trastuzumab plus a
small molecule tyrosine kinase inhibitor (lapatinib, neratinib, or
afatinib), or with 2 different HER2-targeting antibodies. Tras-
tuzumab and pertuzumab bind at different sites on the extracellu-
lar portion of HER2 (domains 4 and 2, respectively) [52]. While
trastuzumab inhibits ligand independent signaling of HER2 and
cleavage of HER2 to p95HER2 (a truncated but constitutively active
form), pertuzumab prevents HER2 from forming dimers with other
HER2 family proteins. Both antibodies elicit antibody-dependent
cell-mediated cytotoxic (ADCC) effects [53–57]. In the first-line
treatment of advanced HER2-positive breast cancer dual inhibition
of HER2 was more effective than inhibition with trastuzumab
alone in the CLEOPATRA trial, where the combination of docetaxel
plus trastuzumab plus pertuzumab resulted in 15.7 months longer
OS as compared with docetaxel plus trastuzumab plus placebo
Table 2
Randomized adjuvant or neoadjuvant/adjuvant trials evaluating longer than 12-month duration of HER-targeted therapy or dual HER2 inhibition.
Study Target group Groups Patients (n) Regimens Median
follow-up
(years)
DFS/EFS
events
(n)
Died (n) DFS/EFS/PFS Overall survival
HERA
[43]
pN + or pN0 with
T > 1 cm
T 12 mo
T 24 mo
1552
1553
ChemoP 4 cycles? T12 mo
ChemoP 4 cycles? T24 mo
8 367
367
186
196
8-y 76.0%
8-y 75.8%
HR 0.99,
P = 0.86
86.4%
87.6%
HR 1.05,
P = 0.63
ExteNET
[46,47]
Stage
I–III
T
T? N
1420
1420
Chemo? T12 mo? Placebo12 mo
Chemo? T12 mo? Neratinib12 mo
2.0 109
70
N.A.
N.A.
2-y 91.6%
2-y 93.9%
HR 0.67,
P = 0.0091
N.A.
N.A.
ALTTO
[74]
pN+, or
pN0 with
TP 1 cm
T
T + L
T? L
L
2097
2093
2091
2100
Chemo? T52 wk
Chemo? L + T52 wk
Chemo? T12 wk? L34 wk
Chemo? L52 wk
4.5 301
254
284
366
135
106
119
168
4-y 86%
4-y 88%
4-y 87%
4-y 82%
HRT+L vs. T 0.84,
P = 0.048;
HRT-L vs.T 0.96,
P = 0.61;
HRL vs. T 1.34,
P < 0.0005
4-y 94%
4-y 95%
4-y 95%4-y 93%
HRT+L vs. T 0.80, P = 0.078;
HRT-L vs. T 0.91, P = 0.433;
HRL vs. T 1.36,
P = 0.007
NeoALTTO
[76]
T2-T4 T
L
T + L
149
154
152
T6 wk?wP + T12 wk?Surg?FECx3?T34 wk
L6 wk?wP + L12 wk?Surg?FECx3?L34 wk
T + L6 wk?wP + T + L12 wk?Surg?FECx3 ?T + L34 wk
3.8 37
38
30
23
18
13
3-y 76%
3-y 78%
3-y 84%
HRL vs. T 1.06,
P = 0.81;
HRT+L vs. T 0.78,
P = 0.33
3-y 90%
3-y 93%
3-y 95%
HRL vs. T 0.86,
P = 0.65;
HRT+L vs. T 0.62, P = 0.19
NeoSphere
[83]
Stage
II or III,
T > 2 cm
D + T
D + T + P
T + P
D + P
107
107
107
96
Dx4 + T12 wk? Surg? FECx3 + T39 wk
Dx4 + T + P12 wk? Surg? FECx3 + T39 wk
T + P12 wk? Surg? Dx4? FECx3 + T39 wk
Dx4 + P12 wk? Surg? FECx3 + T39 wk
5 19
17
27
24
N.A.
N.A.
N.A.
N.A.
5-y 81%
5-y 86%
5-y 73%
5-y 73%
HRDTP vs. DT 0.69 (95% CI, 0.34–1.40);
HRTP vs. DT 1.25
(95% CI, 0.68–2.30);
HRDP vs. DTP 2.05 (95% CI, 1.07–3.93)
N.A.
N.A.
N.A.
N.A.
CI, confidence interval, DFS: disease-free survival; EFS: event-free survival; PFS: progression-free survival; T: trastuzumab; HR: hazard ratio; N: neratinib; N.A., not available; L: lapatinib; wP: weekly paclitaxel; Surg: surgery; FEC;
fluorouracil, epirubicin, cyclophosphamide; P: pertuzumab; D: docetaxel.
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Table 3
Randomized trials evaluating lapatinib, neratinib, pertuzumab, or trastuzumab emtansine as neoadjuvant treatments of HER2-posive breast cancer.
Study Target group Groups No. of
patients
Neoadjuvant regimens Duration of HER2-targeted therapy
(weeks)
pCR (breast) (%) pCR (breast & axilla)
(%)
GeparQuinto
[65]
cN+, higher risk cN0
(ER/PgR-, and
cTP 2 cm)
T
L
307
308
ECx4 + T? Dx4 + T
ECx4 + L? Dx4 + L
24 34.2
26.0
OR 0.68,
P = 0.03
30.3
22.7
OR 0.68,
P = 0.04
NSABP B-41
[66]
cT2–T3, N0–N2a T
L
T + L
181
174
174
ACx4?wPx4 + T
ACx4?wPx4 + L
ACx4?wPx4 + T + L
17
17
18
52.5
53.2
62.0
PT vs. T+L = 0.095
49.4
47.4
60.2
PT vs. T+L = 0.056
NeoALTTO
[67]
cT2-4 T
L
T + L
149
154
152
T6 wk?wP + T12 wk
L6 wk?wP + L12 wk
T + L6 wk?wP + T + L12 wk
18 29.5
24.7
51.3
ORT vs. T+L = 2.6, PT vs.
T+L = 0.0001
27.6
20.0
46.8
ORT vs. T+L = 2.4,
PT vs. T+L = 0.0007
CALGB 40,601
[68]
Stage II or III T
L
L + T
120
67
118
wP + T16wk
wP + L16 wk
wP + T + L16 wk
16
16
16
46
32
56
PT vs. T+L = 0.13
N.A.
N.A.
N.A.
TRIO-US
[69]
Stage
I (cTP 1 cm), II, or III
T
L
T + L
34
36
58
T3 wk? DCbx6 + T18 wk
L3 wk? DCbx6 + L18 wk
T + L3 wk? DCbx6 + T + L18 wk
21
21
21
N.A.
N.A.
N.A.
47
25
52
PT vs. T+L= 0.45
EORTC 10,054
[70]
Stage
cT2–T4
T
L
T + L
53
23
52
Dx3 + T? FECx3 + T
Dx3 + L? FECx3 + L
Dx3 + T + L? FECx3 + T + L
18
18
18
52
46
60
52
36
56
CHER-LOB
[71]
Stage
II–IIIA
T
L
T + L
36
39
46
wP12 wk + T? FECx4 + T
wP12 wk + L? FECx4 + L
wP12 wk + T + L? FECx4 + T + L
26
26
26
N.A.
N.A.
N.A.
25.0
26.3
46.7
P = 0.019
GEICAM 2006–
14
[72]
Stage
I–III
T
L
50
52
ECx4? Dx4 + T
ECx4? Dx4 + L
24
24
52.1
25.5
P = 0.007
47.9
23.5
P = 0.011
Holmes et al.
[73]
Stage
II–III
T
L
T + L
33
34
33
T2 wk? FECx4 + T?wP12 wk + T
L2 wk? FECx4 + L?wP12 wk + L
T + L2 wk? FECx4 + T + L?wP12wk + T
+ L
P26
P26
P26
54
45
74
N.A.
N.A.
N.A.
NSABP FB-7
[81]
Stage
IIB–III
T
N
N + T
42
42
42
wP + T16 wks? ACx4
wP + N16 wks? ACx4
wP + T + N16 wks? ACx4
16
16
16
N.A.
N.A.
N.A.
38.1
33.3
50.0
I-SPY 2
[80]
Stage
II or III
T
N
22
65
wP + T12 wks? ACx4
wP + N12 wks? ACx4
12
12
N.A.
N.A.
23
39
NeoSphere
[82]
Stage
II or III,
T > 2 cm
D + T
D + T + P
T + P
D + P
107
107
107
96
Dx4 + T
Dx4 + T + P
T + P
Dx4 + P
12
12
12
12
29.0
45.8
16.8
24.0
PT vs. T+P = 0.014
21.5
39.3
11.2
17.7
TRYPHAENA
[84]
Stage
II or III
FEC-D
D
DCb
73
75
77
FEC + T + P  3? D + T + P  3
FEC  3? D + T + P  3
D + Cb + T + P  6
18
18
18
61.6
57.3
66.2
50.7%
45.3%
51.9%
KRISTINE
[90]
Stage
II or III
DCb + T
T-DM1
+ P
221
223
DCb + Tx6
T-DM1 + Px6
18
18
N.A.
N.A.
55.7%
44.4%
P = 0.016
HR: hormone receptor; pCR: pathological complete response; PgR: progesterone receptor; T: trastuzumab; L: lapatinib; EC: epirubicin and cyclophosphamide; D: docetaxel; OR: odds ratio; NSABP: National Surgical Adjuvant
Breast and Bowel Project; AC: doxorubicin and cyclophosphamide: wP: weekly paclitaxel; CALGB: Cancer and Leukemia Group B; Cb: carboplatin; N.A.: not available; FEC: fluorouracil, epirubicin, and cyclophosphamide; N:
neratinib; P: pertuzumab; T-DM1: trastuzumab emtansine.
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H. Joensuu / Cancer Treatment Reviews 52 (2017) 1–11 7[58], whereas in the second-line addition of pertuzumab to capeci-
tabine plus trastuzumab did not improve significantly PFS as com-
pared to trastuzumab plus capecitabine in the randomized
PHEREXA trial [59]. Several recent systematic [51,60–63] and other
[64] reviews have discussed HER2-targeted neoadjuvant treat-
ments for early breast cancer.
Lapatinib
Lapatinib, an inhibitor of the HER1 and HER2 tyrosine kinases,
has been compared to trastuzumab in at least 9 randomized trials
as neoadjuvant treatment of HER2-positive breast cancer, 7 of
which evaluated also dual HER2 inhibition with lapatinib plus tras-
tuzumab (Table 3). Three of the trials were large with over 400 par-
ticipating patients [65–67]. Chemotherapy consisted of a taxane
and an anthracycline except for the NeoALTTO and the Cancer
and Leukemia Group B (CALGB) 40,601 trials, where weekly pacli-
taxel was given, and the TRIO-US trial that evaluated the combina-
tion of docetaxel and carboplatin [65–73]. The lapatinib dose was
reduced in several of the trials during the course of the study
due to toxicity, notably diarrhea. The pCR rates achieved with
the lapatinib regimens were similar or smaller than those achieved
with the trastuzumab regimens, whereas the combination of lapa-
tinib plus trastuzumab with chemotherapy resulted in numerically
higher pCR rates as compared to trastuzumab plus chemotherapy
in all 7 studies where dual HER2 inhibition was studied. Yet, the
difference in the pCR rates in favor of the dual HER2 inhibition
was statistically significant only in the NeoALTTO and the CHER-
LOB trials, where the proportion of patients who achieved pCR in
the breast and/or the axilla was approximately 20% higher with
lapatinib plus trastuzumab than with trastuzumab alone.
These consistently favorable pCR rates achieved with the lapa-
tinib plus trastuzumab combination predict that such dual inhibi-
tion of HER2 improves survival outcomes in the adjuvant setting.
To test this hypothesis, 8381 patients from 945 sites were ran-
domly assigned between June 2007 and July 2011 to one of the 4
arms of the ALTTO trial, either trastuzumab alone, trastuzumab
plus concomitant lapatinib, sequential trastuzumab and lapatinib,
or lapatinib alone [74]. The overall duration of each HER2-
targeted therapy was 12 months. The chemotherapy component
varied, and the HER2-targeted therapy was given either after all
chemotherapy, concomitantly with taxane therapy that followed
anthracycline-containing chemotherapy, or concomitantly with
docetaxel plus carboplatin (Table 2). The lapatinib only-group
was closed early due to futility to detect noninferiority of lapatinib
to trastuzumab, and the patients in this group were offered trastu-
zumab. In an analysis performed after a median follow-up time of
4.5 years, the patients who received trastuzumab plus lapatinib
had a smaller hazard for breast cancer recurrence or death than
those treated with trastuzumab alone, but the 97.5% confidence
interval crossed one (HR 0.84, 97.5% CI 0.70–1.02) and the P value
of 0.048 was not significant at set significance level of 0.025. The
patients assigned to receive sequential trastuzumab and lapatinib
had similar DFS as those assigned to trastuzumab. There was no
significant difference in OS between the groups, except that the
patients assigned to lapatinib alone had inferior OS. Cardiac toxic-
ity was low irrespective the type of HER2 inhibition. The patients
treated with lapatinib had more diarrhea, hepatic toxicity, and skin
rash than those treated with trastuzumab. Curiously, patients who
developed skin rash within 6 weeks of lapatinib initiation derived
most benefit from lapatinib-based therapy [75].
A much smaller NeoALTTO trial also evaluated survival of
patients randomly allocated to receive trastuzumab, lapatinib, or
their combination for 1 year (Table 2) [76]. The study was not pow-
ered for this purpose, as event-free survival (EFS) and OS were sec-
ondary endpoints. The patients treated with lapatinib plustrastuzumab tended to have the best EFS, but the EFS or OS com-
parisons with the trastuzumab group were not significant. In the
NeoALTTO patient population the patients assigned to lapatinib
had similar survival as those assigned to trastuzumab.
Taken together, lapatinib may not be as effective as trastuzu-
mab in the adjuvant or neoadjuvant treatment of early HER2-
positive breast cancer, in accordance with the efficacy comparisons
done in the advanced breast cancer setting [77,78]. The reasons
remain speculative, but the capability of trastuzumab to elicit
ADCC could be important [79]. On the other hand, dual HER2 inhi-
bition with trastuzumab plus lapatinib appears slightly more effec-
tive than trastuzumab alone, but no significant advantage in DFS or
OS has been demonstrated, and the combination is associated with
greater toxicity and cost. Even relatively mild non-hematological
toxicity, such as diarrhea, might influence compliance in the adju-
vant setting due to its long duration. The currently available data
suggest that the combination of adjuvant trastuzumab plus lapa-
tinib cannot be recommended as the standard of care for patients
with early HER2-positive breast cancer [74].
Neratinib
Two randomized trials, NSABP FB-7 and I-SPY 2, compared ner-
atinib to trastuzumab in combination with weekly paclitaxel, each
followed by 4 cycles of AC, as neoadjuvant treatment of early
HER2-positive breast cancer (Table 3). The neratinib-containing
regimen graduated as likely more effective compared with the
trastuzumab-containing regimen in the I-SPY 2 trial in the subset
of patients with HER2-positive, hormone receptor-negative cancer
[80]. On the other hand, in the FB-7 trial the trastuzumab regimen
was numerically slightly more effective in this subgroup of
patients [81]. In each trial the number of patients with HER2-
positive, hormone receptor-negative cancer was small. The combi-
nation of neratinib, trastuzumab, and paclitaxel was also evaluated
in the FB-7 trial resulting in a higher pCR rate (50.0%) as compared
with the trastuzumab or neratinib regimens (38.1% and 33.3%,
respectively) in the entire patient population with HER2-positive
cancer [81].
Pertuzumab
Pertuzumab is the first drug approved based on pCR as the
endpoint. It was approved for the neoadjuvant treatment of
HER2-positive breast cancer mostly based on the findings in the
NeoSphere trial that accrued 417 patients from 59 centers from
December 2007 to December 2009 [82]. NeoSphere compares 4
regimens, docetaxel plus concomitant trastuzumab, docetaxel plus
trastuzumab and pertuzumab, trastuzumab plus pertuzumab
(without docetaxel), and docetaxel plus pertuzumab. A higher
pCR rate in the breast was obtained with the combination of
docetaxel, trastuzumab, and pertuzumab than with docetaxel plus
trastuzumab (45.8% and 29.0%, respectively; P = 0.014; Table 3).
The trastuzumab plus pertuzumab and the docetaxel plus
pertuzumab combinations yielded somewhat lower pCR rates.
The patients in each group were treated with trastuzumab after
surgery to complete 12 months of HER2-targeted therapy (Table 2).
After a median follow-up time of 5 years progression-free survival
(PFS) tended to be higher in the docetaxel plus trastuzumab plus
pertuzumab group as compared with the docetaxel plus trastuzu-
mab group (HR 0.69, 95% CI 0.34–1.40). Patients treated with doc-
etaxel and pertuzumab had less favorable PFS. OS results were not
reported [83]. Pertuzumab plus trastuzumab without docetaxel
was associated with the least side-effects, the most common one
being grade 1–2 diarrhea (28%) [82]. Little cardiac toxicity was
recorded in NeoSphere, which is in agreement with the findings
in the TRYPHAENA study, where trastuzumab plus pertuzumab
8 H. Joensuu / Cancer Treatment Reviews 52 (2017) 1–11was evaluated with 3 different chemotherapy backbones for car-
diac toxicity (Table 3) [84].
Despite the absence of statistically significant PFS improvement
in the NeoSphere patient population, the overall results are
encouraging for the triple combination docetaxel, trastuzumab,
and pertuzumab, as this combination improved substantially the
pCR rate and was relatively well tolerated. This combination was
effective also in the treatment of advanced HER2-positive breast
cancer [58]. Therefore, the results of the APHINITY trial
(NCT01358877) that compares chemotherapy plus trastuzumab
plus pertuzumab to chemotherapy plus trastuzumab plus placebo
as adjuvant treatments of early HER2-positive breast cancer are
awaited with interest. APHINITY accrued 4800 patients between
October 2011 and August 2013, and the first results are expected
in the near future.
Afatinib
Afatinib is an irreversible inhibitor of the ERBB2 family of tyro-
sine kinases [85]. In the non-randomized, neoadjuvant DAFNE trial,
afatinib (20 mg/d) was administered together with trastuzumab
and weekly paclitaxel, followed by epirubicin, cyclophosphamide,
and trastuzumab [86]. Of the 65 patients treated, 49% achieved
pCR in the breast and the axilla. The most frequent nonhematologic
grade 3–4 adverse effects included diarrhea (8%) and infection
(5%), 1 patient had congestive heart failure. A randomized study
comparing afatinib to lapatinib and to trastuzumab as neoadjuvant
agents was stopped early due to slow enrollment [87].
Ado-trastuzumab emtansine (T-DM1)
T-DM1 is an antibody drug conjugate where the microtubule
toxin emtansine is linked with trastuzumab. After binding to
HER2 the conjugate is internalized and the payload (emtansine)
is released within the cell, resulting in cell death. T-DM1 was effec-
tive in the treatment of advanced HER2-positive breast cancer in
patient population refractory to trastuzumab and had a favorable
safety profile [88,89].
In the KRISTINE trial (NCT02131064) 444 patients were ran-
domly assigned to receive 6 cycles of T-DM1 plus pertuzumab or
TCH (Table 3). While the pCR rate favored TCH (56% vs. 44%;
P = 0.016), gradeP 3 adverse events where substantially less fre-
quent in the T-DM1 plus pertuzumab arm (13% vs. 64%) [90].
The KAITLIN trial (NCT01966471) compares adjuvant T-DM1
plus pertuzumab to trastuzumab, pertuzumab, and a taxane
(weekly paclitaxel or docetaxel), each given after anthracyclines,
as treatments for node-positive or high-risk node-negative HER2-
positive breast cancer. KAITLIN is fully recruited with 1846
patients entered. The KATHERINE trial (NCT01772472) compares
T-DM1 to trastuzumab as adjuvant treatments of patients with
HER2-positive breast cancer with residual disease after neoadju-
vant therapy. The duration of HER2-targeted therapy is 12 months
in these trials. No results are yet available.Concluding remarks
Despite no significant survival advantage in favor of the trastu-
zumab plus lapatinib combination was found in ALTTO, dual inhi-
bition of HER2 remains a promising strategy. The discovery of
novel, synergistic, and well-tolerated drug combinations is an
important goal [80], and may be more important than the chase
for the optimal duration of administration of single HER2-
targeting agents in the adjuvant setting. Highly effective combina-
tion regimens may allow also a short duration of administration.For example, a brief duration of the docetaxel, trastuzumab, plus
pertuzumab combination is being compared with chemotherapy
plus 12-months of trastuzumab in the BOLD-1 trial
(NCT02625441). Both the escalation and de-escalation trials being
conducted are likely important for the optimization of HER2-
targeted adjuvant treatments. Several of such trials will report
the first results in the near future, and may modify the current
standard treatment of the patients with HER2-positive early breast
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